Boehringer Ingelheim Press Releases

Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors

BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events

European Respiratory Society (ERS) Awards Annual COPD Research Prize

Boehringer Ingelheim expands its Business with Biosimilars

New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis

Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives approval in the EU

Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD

New data for once-daily linagliptin show durable efficacy over two years

Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe

Boehringer Ingelheim wins Frost & Sullivan Award for Biopharmaceutical Contract Manufacturing

€1 million awarded to winning projects which aim to prevent atrial fibrillation-related stroke

Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib*

Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke over warfarin in patients with atrial fibrillation taking antiplatelet or other concomitant therapies

Pradaxa® (dabigatran etexilate) revolutionizes stroke prevention in atrial fibrillation

Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe

Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology

Positive first half-year 2011 for Boehringer Ingelheim – new growth from innovative medicines /Pradaxa approved in Europe

Breakthrough therapy PRADAXA® (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in EU